US States Face Steep Decline in J&J COVID Vaccine Amid Production Problems

Johnson & Johnson is scaling back shipments of its single-dose COVID-19 vaccine by 86% next week as it grapples with manufacturing issues at a major plant in Baltimore.
The government has allocated only 700,000 J&J shots to states next week, down from 4.9 million the week prior, according to data from the Centers for Disease Control and Prevention.